TW202216694A - 使用雜芳基-聯苯醯胺衍生物治療癌症之方法 - Google Patents

使用雜芳基-聯苯醯胺衍生物治療癌症之方法 Download PDF

Info

Publication number
TW202216694A
TW202216694A TW110122725A TW110122725A TW202216694A TW 202216694 A TW202216694 A TW 202216694A TW 110122725 A TW110122725 A TW 110122725A TW 110122725 A TW110122725 A TW 110122725A TW 202216694 A TW202216694 A TW 202216694A
Authority
TW
Taiwan
Prior art keywords
group
cancer
compound
agents
formula
Prior art date
Application number
TW110122725A
Other languages
English (en)
Chinese (zh)
Inventor
世杰 李
科洛梅爾 馬爾塔 維拉塔
曾一斌
朋烈 張
Original Assignee
美商卡默森屈有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商卡默森屈有限公司 filed Critical 美商卡默森屈有限公司
Publication of TW202216694A publication Critical patent/TW202216694A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110122725A 2020-06-23 2021-06-22 使用雜芳基-聯苯醯胺衍生物治療癌症之方法 TW202216694A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
US63,042,807 2020-06-23

Publications (1)

Publication Number Publication Date
TW202216694A true TW202216694A (zh) 2022-05-01

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110122725A TW202216694A (zh) 2020-06-23 2021-06-22 使用雜芳基-聯苯醯胺衍生物治療癌症之方法

Country Status (14)

Country Link
US (3) US20210393759A1 (https=)
EP (1) EP4167991A4 (https=)
JP (1) JP7804596B2 (https=)
KR (1) KR20230040993A (https=)
CN (1) CN116472045B (https=)
AU (1) AU2021297216B2 (https=)
BR (1) BR112022026397A2 (https=)
CA (1) CA3187605A1 (https=)
CL (1) CL2022003716A1 (https=)
CO (1) CO2023000703A2 (https=)
IL (1) IL299206A (https=)
MX (1) MX2022016554A (https=)
TW (1) TW202216694A (https=)
WO (1) WO2021262627A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448938A (zh) * 2009-03-27 2012-05-09 阿迪生物科学公司 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JP7101678B2 (ja) * 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10919852B2 (en) * 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
CA3092362A1 (en) * 2017-10-19 2019-04-25 Tempest Therapeutics, Inc. Picolinamide compounds
CR20200347A (es) * 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US10568874B2 (en) * 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
JP7736678B2 (ja) * 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド

Also Published As

Publication number Publication date
US20240115682A1 (en) 2024-04-11
AU2021297216B2 (en) 2025-10-16
BR112022026397A2 (pt) 2023-03-14
AU2021297216A1 (en) 2023-02-02
IL299206A (en) 2023-02-01
CO2023000703A2 (es) 2023-01-26
US20210393759A1 (en) 2021-12-23
CN116472045A (zh) 2023-07-21
WO2021262627A1 (en) 2021-12-30
CN116472045B (zh) 2025-05-13
CA3187605A1 (en) 2021-12-30
US20250090646A1 (en) 2025-03-20
MX2022016554A (es) 2023-04-10
EP4167991A4 (en) 2024-07-24
JP7804596B2 (ja) 2026-01-22
KR20230040993A (ko) 2023-03-23
CL2022003716A1 (es) 2023-06-30
EP4167991A1 (en) 2023-04-26
JP2023531970A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
TWI873098B (zh) 用於治療與sting活性相關之病症的化合物及組合物
TW202216694A (zh) 使用雜芳基-聯苯醯胺衍生物治療癌症之方法
TWI873145B (zh) 用於治療與sting活性相關之病狀的化合物及組合物
CN111225665B (zh) 大环免疫调节剂
ES2816060T3 (es) Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
TWI734715B (zh) 趨化因子受體調節劑
TW202136255A (zh) 用於治療與ｓｔｉｎｇ活性相關之病狀的化合物及組合物
TW202136239A (zh) 用於治療與ｓｔｉｎｇ活性相關之病狀的化合物及組合物
TW202043198A (zh) 用於治療與sting活性相關之病況的化合物及組合物
CN114206338B (zh) 作为pd-l1抑制剂的二氢化茚类
CN114340633A (zh) 用于治疗pd-l1疾病的三芳基化合物
TW202126622A (zh) 用於治療與ｓｔｉｎｇ活性相關之病狀的化合物及組合物
KR20180134395A (ko) Nlrp3 조정제
TW202128651A (zh) 用於治療ｐｄ－ｌ１疾病之雜芳基－聯苯基醯胺
CA2921568A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
TW202235073A (zh) 用於治療與sting活性相關的病狀之化合物及組合物
TW202334084A (zh) 用於治療與sting活性相關之病況的化合物及組合物
AU2024331602A1 (en) Bcl6 bifunctional degraders
CN116964045A (zh) 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物
KR102848138B1 (ko) 인터루킨 1 베타와 관련된 병태를 치료하기 위한 피리딘-설폰아미드 화합물
EA049712B1 (ru) Способы лечения рака с использованием производных гетероарилбифениламида
JP2024502648A (ja) 架橋ヘテロシクリル置換ピリミジン化合物、その調製方法及び医学的使用
EA040670B1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak